Drug Profile

Luveltamab tazevibulin - Sutro Biopharma

Alternative Names: anti-FolRa ADC STRO-002; anti-FolRalpha ADC STRO-002; FolR-alpha-ADC-Sutro-Biopharma; Luvelta; STRO-002

Latest Information Update: 16 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sutro Biopharma
Developer Gynecologic Oncology Group; Sutro Biopharma; Tasly Biopharmaceuticals
Class Amides; Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Indoles
Mechanism of Action Tubulin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Acute myeloid leukaemia
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Phase I Ovarian cancer
Suspended Acute myeloid leukaemia; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Peritoneal cancer; Solid tumours

16 Jun 2026 Sutro Biopharma terminates a phase-II/III clinical trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater) in Australia, Austria, Belgium, Canada, Czech Republic, Finland, Germany, Hungary, Ireland, Israel, Italy, New Zealand, Singapore, South Korea, Spain, Switzerland, United Kingdom, USA (IV) due to strategic business considerations (NCT05870748)
30 Dec 2025 Tasly Pharmaceutical Group completes a phase I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy) in China (IV) (NCT06238687)
24 Aug 2025 Sutro Biopharma terminates phase I/II REFRαME P1 trial in Acute myeloid leukemia (In neonates, In infants, In children, Second-line or greater therapy) in Austria, Canada, Denmark, France, Germany, Italy, Netherlands, Spain and USA (IV) (NCT06679582)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com